Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform Finland Oyj : Plc – Manager's transactions – Gonšalo Andrade

06/14/2021 | 08:26am EDT

Company release

Nanoform Finland Plc

June 14, 2021

03:00 p.m. Finnish time / 02:00 p.m. Swedish time

Nanoform Finland Plc - Manager's transactions - Gonçalo Andrade

Helsinki, Finland- Manager's transaction related to Nanoform Finland Plc's other senior manager Gonçalo Andrade's share subscription with stock options from option program 2/2019.

____________________________________________

Person subject to the notification requirement

Name: Gonçalo Andrade

Position: Other senior manager

Issuer: Nanoform Finland Plc

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 743700JJO2NU8LBS1592_20210614115630_2

____________________________________________

Transaction date: 2021-06-11

Venue not applicable

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: EXERCISE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 45,000 Unit price: 1.1 EUR

Aggregated transactions

(1): Volume: 45,000 Volume weighted average price: 1.1 EUR

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com / +358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com

Disclaimer

Nanoform Finland Oyj published this content on 14 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2021 12:25:03 UTC.


ę Publicnow 2021
All news about NANOFORM FINLAND OYJ
06/14NANOFORM FINLAND OYJ : Plc – Manager's transactions – Gonçalo Andrad..
PU
06/14NANOFORM FINLAND PLC : - Manager's transactions - Gonçalo Andrade
AQ
06/11NANOFORM FINLAND OYJ : Share subscriptions based on Nanoform Finland Plc's multi..
PU
06/11NANOFORM FINLAND OYJ : The Board of Directors of Nanoform Finland Plc decided on..
AQ
06/11NANOFORM FINLAND OYJ : Share subscriptions based on Nanoform Finland Plc's multi..
AQ
06/02NANOFORM FINLAND OYJ : Upgrades Business Targets For 2025; Shares Up 8%
MT
06/02NANOFORM FINLAND OYJ : raises its mid-term business targets for 2025
AQ
05/29Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement End..
CI
05/27NANOFORM FINLAND OYJ : Interim Report January – March (Q1) 2021
PU
05/27NANOFORM FINLAND OYJ : Interim Report January - March (Q1) 2021
AQ
More news
Financials
Sales 2021 2,85 M 3,38 M 3,38 M
Net income 2021 - - -
Net cash 2021 74,9 M 88,9 M 88,9 M
P/E ratio 2021 -26,3x
Yield 2021 -
Capitalization 524 M 623 M 623 M
EV / Sales 2021 158x
EV / Sales 2022 50,2x
Nbr of Employees 87
Free-Float 68,0%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 7,10 €
Average target price 9,15 €
Spread / Average Target 28,9%
EPS Revisions
Managers and Directors
Edward HŠggstr÷m Chief Executive Officer
Albert Alexander HŠggstr÷m Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonšalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ0.28%611
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348